Testing Denikitug for advanced stomach and esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new drug called denikitug, alone or combined with other cancer treatments, for patients with advanced stomach, gastroesophageal junction, or esophageal adenocarcinoma that has progressed after initial treatment. The drug targets immune cells to help your body fight cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed diagnosis of metastatic (spread) or unresectable gastric, gastroesophageal junction, or esophageal adenocarcinoma
- Your tumor must be HER2-negative (a genetic marker determined by biopsy)
- Your cancer must have progressed after at least one prior treatment with chemotherapy, immunotherapy (PD-1/PD-L1), or claudin-18-targeted therapy
- Good overall health and functional ability (ECOG score 0–1: able to carry out normal activities with minimal limitations)
- Adequate organ function (heart, liver, kidneys working well enough for treatment)
- No history of autoimmune disease, inflammatory bowel disease, or lung inflammation requiring steroids in the past 2 years
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests new drug combinations for people with advanced stomach or esophageal cancer that worsened after first treatment. It aims to find better options for those whose tumors lack HER2.
This trial tests a new combination of three drugs for stomach cancer that has progressed after initial immunotherapy. It aims to see if this combo can shrink tumors or slow cancer growth, potentially offering a new option for patients like you.
This trial tests a combination of three drugs—disitamab vedotin, tunlametinib, and a PD-1 antibody—for people with advanced stomach cancer that has HER2 (a protein that helps cancer grow). The goal is to see if this combo can shrink tumors or slow the cancer, and whether it's safe.
This trial tests a new drug, TRK-950, added to standard chemotherapy (ramucirumab and paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has worsened after previous treatment. The goal is to see if this combination can help shrink tumors or slow disease progression.
This trial tests a new drug called denikitug, given alone or combined with other cancer treatments, for patients with advanced colorectal cancer that hasn't responded to previous treatments. The goal is to help people whose cancer has a specific genetic profile (MSS) that doesn't respond well to standard immunotherapy alone.
This trial tests a combination of two drugs—nab-paclitaxel (a chemotherapy drug) and cadonilimab (an immunotherapy drug)—for people with advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this combination can help shrink or control the cancer when other treatments haven't been tried yet.
Hear when a new HER2-negative trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.